Clinical efficacy and chemoresistance analysis of precision neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a prospective, single-arm pilot study
PDO-based NAC shows a promising resectable rate in BRPC patients, with good tolerance. Potential drug-resistant and sensitive genes and cell-cell interaction changes may participate in the development of gemcitabine resistance.
Authors
- Yinan Zhu (ORCID: https://orcid.org/0000-0002-1034-8882)
- Yonggang He
- Weiwei Wang (ORCID: https://orcid.org/0000-0001-8698-4474)
- Jing Li (ORCID: https://orcid.org/0000-0003-3707-6570)
- Zheng Wang (ORCID: https://orcid.org/0000-0003-4838-0965)
- Chongyu Zhao
- Lu Zheng (ORCID: https://orcid.org/0000-0002-1619-6525)
- Xiaobing Huang (ORCID: https://orcid.org/0009-0001-2083-7663)
- Yuqing Yi
Institutions
- Army Medical University (CN)
- Dalian Medical University (CN)
- Shantou University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- First Affiliated Hospital of Shantou University Medical College (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1097/js9.0000000000002342
- Citations
- 6
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 6.27